Egle Therapeutics SAS
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Egle Therapeutics SAS
The London-based biotech is hoping to turn the dream of liver organ transplant without the need for lifelong immunosuppression into reality.
Private Company Edition: Flagship’s Pioneering Medicines initiative and the firm’s portfolio companies will deliver cystic fibrosis drug candidates. Also, recent venture capital financings include cloud technology firm Saama’s $430m round and Shoreline’s $140m in new funding.